Arrowhead Pharmaceuticals

Happy Hispanic Heritage Month! 🎉 At Arrowhead Pharmaceuticals, we celebrate the rich culture, history, and contributions of the Hispanic and Latinx communities. This month, we honor the diverse voices and stories that shape our workforce and the communities we serve. Recently, we held a vibrant celebration for Mexican Independence Day, filled with delicious food, music, and cultural decorations. We’re committed to creating an inclusive environment where everyone feels valued and empowered. Together, we can continue to drive innovation and improve health outcomes for all. Join us in recognizing the achievements and impact of Hispanic and Latinx individuals in our industry and beyond. Check out some highlights from our celebration below! #HispanicHeritageMonth #DiversityAndInclusion #Pharmaceuticals #CulturalHeritage #TogetherWeThrive #ArrowheadPharmaceuticals

1 in 5 U.S. deaths are related to heart disease, making it more important than ever to act. On #WorldHeartDay, we're advancing our pipeline to develop potential treatments to combat cardiovascular disease and improve the lives of patients. Learn more: https://bit.ly/3XUTz5y

September is National #CholesterolEducationMonth and we’re shedding light on the role of cholesterol found in triglyceride-rich lipoproteins. Elevated levels of these fats in the blood play a significant role in the development of #CardiovascularDisease. Our investigational #RNAi therapeutic may help lower these levels in people with elevated triglycerides.

It’s #FHAwarenessDay, and we’re spreading awareness of #FamilialHypercholesterolemia, a rare genetic disorder causing high LDL cholesterol from birth. At Arrowhead, we’re committed to supporting patients living with lipid conditions. Learn more about FH Day: https://bit.ly/4dhgdJF #KnowFH

We’re excited for the final webinar in our Summer Series, highlighting our candidates in our pipeline targeting the #CNS. Please note the updated date is Monday, October 7th at 4:30 PM EDT. Register here: https://lnkd.in/e_k7r_7B

Today, we announced that we have filed for regulatory clearance with the New Zealand Medicines and Medical Devices Safety Authority to initiate a Phase 1/2a study of ARO-INHBE, our novel #RNAi candidate for the treatment of obesity. Learn more here: https://lnkd.in/eYCw7SaP

📚🎒 Arrowhead Pharmaceuticals Gives Back: Back to School Supplies & Backpack Packing Event! 🎒📚   At Arrowhead Pharmaceuticals, we’re committed to making a positive impact beyond our labs and into our community. We’re thrilled to showcase our recent initiative supporting local students as they gear up for the new school year! 🌟   Here’s How We’re Making a Difference:   🛒 Supplies Donation: Our team collected a variety of essential school supplies, including notebooks, pens, and markers. We are proud to contribute these much-needed items to ensure that every student is prepared for success. 🎒 Backpack Packing: Our dedicated employees came together to pack these supplies into backpacks. It was inspiring to see everyone working hand-in-hand to create a tangible impact for the students in our community.   Our goal is to support educational success and foster a sense of community spirit. Thank you to everyone who participated and donated. Your generosity truly makes a difference! Let’s continue to support our community and inspire the next generation. Together, we can achieve great things! 🌟   #WeAreArrowhead #CommunityInvolvement #BackToSchool #GivingBack #Philanthropy #EducationSupport #TeamEffort

Today, we announced that the FDA has granted Breakthrough Therapy designation for our #RNAi candidate for familial chylomicronemia syndrome (#FCS). This milestone marks important progress toward bringing potential treatments to patients living with FCS. Learn more: https://bit.ly/3TlglAI

We’re attending the National Lipid Association 2024 Fall Clinical Lipid Update! We're looking forward to meeting with peers & health professionals as we work to advance lipid care. Visit us at booth #101 to learn how we’re supporting patients affected by abnormal lipid levels. More: https://bit.ly/4gsbUyj

This morning, our webinar featuring Dr. Gerald Watts took a deep dive into the results from our PALISADE phase 3 study of investigational plozasiran presented at #ESCCongress 2024. Listen to the recording here: https://lnkd.in/gUnztEgV